Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
Provided By GlobeNewswire
Last update: Jun 2, 2025
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –
Read more at globenewswire.com3.02
-0.68 (-18.38%)
Find more stocks in the Stock Screener
CRDF Latest News and Analysis
a day ago - ChartmillTop movers in Tuesday's after hours sessionWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
